Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
[[:Category:Antianginals|Antianginal]] (1) ·
[[:Category:Antihistamines|Antihistamine]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]] (1) ·
[[:Category:Insulin_secretagogues|Insulin secretagogue]] (1) ·
[[:Category:Nitrates|Organic nitrate]] (1) ·
[[:Category:Sulfonylureas|Sulfonylurea (third-generation)]] (1) ·
[[:Category:Vasodilators|Vasodilator]] (1)
1-2 mg PO once daily with breakfast; titrate by glycemic response (1) ·
60 mg PO BID or 180 mg PO once daily (1) ·
Isosorbide mononitrate ER: 30-60 mg PO once daily in the morning, titrate to 120-240 mg/d; isosorbide dinitrate IR: 5-20 mg PO TID with a 12-14 hour nitrate-free interval to prevent tolerance (1)
Mononitrate ~100% (no first-pass; the principal advantage over dinitrate); dinitrate ~20%'"`UNIQ--ref-00001462-QINU`"' (1) ·
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) ·
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' (1)
Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 3 results in range #1 to #3.


